Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Sekvencia:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas č. : 159519-65-0
Molekulový vzorec : C204H301N51O64
Molekulová hmotnosť : 4492
Čistota (HPLC) : 98.0%min.
Vzhľad : White to off-white amorphous solid
Jediná nečistota (HPLC) : 0.5%max
Aminokyselinové zloženie : ±10% of theoretical
Obsah peptidov (N %) : ≥80,0 %
Obsah vody (Karl Fischer) : ≤ 8,0 %
TrifluoroAcetate Content(HPIC) : ≤12.0%
čs (ESI) : Konzistentné
Mass Balance : 95.0~105,0 %
stupňa : Farmaceutická trieda
Skladovanie: ZATVORENÉ, nižšie 2 ~ 8℃ preservation
Použitie : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtid (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
